Logo image of GUTS

FRACTYL HEALTH INC (GUTS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GUTS - US35168W1036 - Common Stock

1.4 USD
+0.11 (+8.53%)
Last: 11/21/2025, 8:00:01 PM
1.38 USD
-0.02 (-1.43%)
After Hours: 11/21/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GUTS. GUTS was compared to 188 industry peers in the Health Care Equipment & Supplies industry. GUTS has a bad profitability rating. Also its financial health evaluation is rather negative. GUTS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

GUTS had negative earnings in the past year.
GUTS had a negative operating cash flow in the past year.
In the past 5 years GUTS always reported negative net income.
In the past 5 years GUTS always reported negative operating cash flow.
GUTS Yearly Net Income VS EBIT VS OCF VS FCFGUTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

GUTS has a worse Return On Assets (-106.94%) than 79.26% of its industry peers.
Industry RankSector Rank
ROA -106.94%
ROE N/A
ROIC N/A
ROA(3y)-97.75%
ROA(5y)-92.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GUTS Yearly ROA, ROE, ROICGUTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

GUTS's Gross Margin of 100.00% is amongst the best of the industry. GUTS outperforms 100.00% of its industry peers.
The Profit Margin and Operating Margin are not available for GUTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GUTS Yearly Profit, Operating, Gross MarginsGUTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

3

2. Health

2.1 Basic Checks

GUTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GUTS has been increased compared to 1 year ago.
The number of shares outstanding for GUTS has been increased compared to 5 years ago.
The debt/assets ratio for GUTS has been reduced compared to a year ago.
GUTS Yearly Shares OutstandingGUTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
GUTS Yearly Total Debt VS Total AssetsGUTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.55, we must say that GUTS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.55, GUTS is doing worse than 72.34% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.55
ROIC/WACCN/A
WACC8.15%
GUTS Yearly LT Debt VS Equity VS FCFGUTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

GUTS has a Current Ratio of 4.27. This indicates that GUTS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.27, GUTS is in the better half of the industry, outperforming 72.87% of the companies in the same industry.
A Quick Ratio of 4.27 indicates that GUTS has no problem at all paying its short term obligations.
The Quick ratio of GUTS (4.27) is better than 79.26% of its industry peers.
Industry RankSector Rank
Current Ratio 4.27
Quick Ratio 4.27
GUTS Yearly Current Assets VS Current LiabilitesGUTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

3

3. Growth

3.1 Past

GUTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -59.13%.
GUTS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -96.91%.
EPS 1Y (TTM)-59.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.92%
Revenue 1Y (TTM)-96.91%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

GUTS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.16% yearly.
The Revenue is expected to grow by 337.37% on average over the next years. This is a very strong growth
EPS Next Y0.8%
EPS Next 2Y15.3%
EPS Next 3Y10.02%
EPS Next 5Y8.16%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y451.79%
Revenue Next 5Y337.37%

3.3 Evolution

GUTS Yearly Revenue VS EstimatesGUTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 50M 100M 150M
GUTS Yearly EPS VS EstimatesGUTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 -10 -20 -30

0

4. Valuation

4.1 Price/Earnings Ratio

GUTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GUTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GUTS Price Earnings VS Forward Price EarningsGUTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GUTS Per share dataGUTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.3%
EPS Next 3Y10.02%

0

5. Dividend

5.1 Amount

GUTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

FRACTYL HEALTH INC

NASDAQ:GUTS (11/21/2025, 8:00:01 PM)

After market: 1.38 -0.02 (-1.43%)

1.4

+0.11 (+8.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-03 2026-03-03/amc
Inst Owners53.84%
Inst Owner Change209.93%
Ins Owners2.94%
Ins Owner Change0%
Market Cap184.55M
Revenue(TTM)3.00K
Net Income(TTM)-122.20M
Analysts85.45
Price Target7.18 (412.86%)
Short Float %5.58%
Short Ratio1.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-87.75%
Min EPS beat(2)-120.28%
Max EPS beat(2)-55.23%
EPS beat(4)0
Avg EPS beat(4)-48.37%
Min EPS beat(4)-120.28%
Max EPS beat(4)-0.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.98%
PT rev (3m)5.6%
EPS NQ rev (1m)17.8%
EPS NQ rev (3m)26.33%
EPS NY rev (1m)0%
EPS NY rev (3m)10.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61516
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -106.94%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-97.75%
ROA(5y)-92.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.35%
Cap/Sales 26233.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.27
Quick Ratio 4.27
Altman-Z -7.55
F-Score2
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)132.87%
Cap/Depr(5y)81.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.92%
EPS Next Y0.8%
EPS Next 2Y15.3%
EPS Next 3Y10.02%
EPS Next 5Y8.16%
Revenue 1Y (TTM)-96.91%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y451.79%
Revenue Next 5Y337.37%
EBIT growth 1Y-21.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.19%
EBIT Next 3Y-14.78%
EBIT Next 5Y-8.7%
FCF growth 1Y-93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-92.21%
OCF growth 3YN/A
OCF growth 5YN/A

FRACTYL HEALTH INC / GUTS FAQ

What is the fundamental rating for GUTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to GUTS.


Can you provide the valuation status for FRACTYL HEALTH INC?

ChartMill assigns a valuation rating of 0 / 10 to FRACTYL HEALTH INC (GUTS). This can be considered as Overvalued.


How profitable is FRACTYL HEALTH INC (GUTS) stock?

FRACTYL HEALTH INC (GUTS) has a profitability rating of 1 / 10.


What is the financial health of FRACTYL HEALTH INC (GUTS) stock?

The financial health rating of FRACTYL HEALTH INC (GUTS) is 3 / 10.


What is the expected EPS growth for FRACTYL HEALTH INC (GUTS) stock?

The Earnings per Share (EPS) of FRACTYL HEALTH INC (GUTS) is expected to grow by 0.8% in the next year.